Senti Biosciences Inc (NASDAQ:SNTI) — Market Cap & Net Worth
Market Cap & Net Worth: Senti Biosciences Inc (SNTI)
Senti Biosciences Inc (NASDAQ:SNTI) has a market capitalization of $21.87 Million ($21.87 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24753 globally and #5050 in its home market, demonstrating a 0.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Senti Biosciences Inc's stock price $1.02 by its total outstanding shares 26290838 (26.29 Million). Analyse Senti Biosciences Inc cash conversion from operations to see how efficiently the company converts income to cash.
Senti Biosciences Inc Market Cap History: 2021 to 2026
Senti Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $2.59 Billion to $26.82 Million (-60.50% CAGR).
Index Memberships
Senti Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #719 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2360 of 3165 |
Weight: Senti Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Senti Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Senti Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
87.72x
Senti Biosciences Inc's market cap is 87.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.59 Billion | $2.29 Million | -$55.32 Million | 1131.50x | N/A |
| 2022 | $370.70 Million | $4.29 Million | -$45.79 Million | 86.49x | N/A |
| 2023 | $173.52 Million | $1.98 Million | -$71.06 Million | 87.72x | N/A |
Competitor Companies of SNTI by Market Capitalization
Companies near Senti Biosciences Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Senti Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Senti Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Senti Biosciences Inc's market cap moved from $2.59 Billion to $ 26.82 Million, with a yearly change of -60.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $26.82 Million | -1.92% |
| 2025 | $27.34 Million | -70.37% |
| 2024 | $92.28 Million | -46.82% |
| 2023 | $173.52 Million | -53.19% |
| 2022 | $370.70 Million | -85.70% |
| 2021 | $2.59 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Senti Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.87 Million USD |
| MoneyControl | $21.87 Million USD |
| MarketWatch | $21.87 Million USD |
| marketcap.company | $21.87 Million USD |
| Reuters | $21.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more